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Abstract: Memantine received marketing authorization from the European Agency for the Evaluation of Medicinal Prod-
ucts (EMEA) for the treatment of moderately severe to severe Alzheimer´s disease (AD) in Europe on 17
th May 2002 and 
shortly thereafter was also approved by the FDA for use in the same indication in the USA. Memantine is a moderate af-
finity, uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist with strong voltage-dependency and fast kinet-
ics. Due to this mechanism of action (MOA), there is a wealth of other possible therapeutic indications for memantine and 
numerous preclinical data in animal models support this assumption. This review is intended to provide an update on pre-
clinical studies on the pharmacodynamics of memantine, with an additional focus on animal models of diseases aside from 
the approved indication. For most studies prior to 1999, the reader is referred to a previous review [196]. 
In general, since 1999, considerable additional preclinical evidence has accumulated supporting the use of memantine in 
AD (both symptomatic and neuroprotective). In addition, there has been further confirmation of the MOA of memantine 
as an uncompetitive NMDA receptor antagonist and essentially no data contradicting our understanding of the benign side 
effect profile of memantine. 
THERAPEUTIC TARGET 
  The maximal therapeutically-relevant plasma concentra-
tion of memantine is around 1 M (see [55, 203]). Brain 
extracellular fluid (ECF) concentration of around 0.8 M can 
be anticipated [102] and any receptor that expresses an affin-
ity at, or below, the very low M range should be considered 
as a potential therapeutic target. Given this assumption, there 
are only four plausible known target types to date: the most
likely is the NMDA receptor channel, but 5-hydroxy-trypta-
mine (5-HT3) receptors [220] and 7 and/or 42 nicotinic 
receptors [11] should also be taken into consideration [11, 
37, 165]. 
 The  7 and 42 nicotinic acetylcholine receptor and the 
5-HT3 receptor systems have been suggested to play a role in 
modulating CNS functions, including learning and memory. 
These receptors are structurally related, containing large ex-
tracellular ligand-binding domains and four transmembrane 
domains that are largely conserved. They exhibit consider-
able cross-pharmacology, e.g. high concentrations of the 7
nAChR agonist nicotine inhibit 5-HT3 receptor-mediated 
responses, and high concentrations of the 5-HT3 receptor 
agonist serotonin inhibit 7 nAChR-mediated responses. 
Based on this knowledge, it seems reasonable to investigate 
whether ligands specific for either receptor, might have af-
finity for both.  
NMDA RECEPTORS 
Fast Kinetics and Strong Voltage-Dependency 
  Memantine blocks the NMDA receptor channel in an 
use-dependent manner, meaning that it can only gain access 
to the channel in the presence of agonist and remains largely  
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trapped in the channel following removal of agonist [113, 
196, 198]. Both the clinical tolerability and symptomatic 
effects of memantine have been attributed to its moderate 
affinity (IC50 around 1M at –70 mV) and associated fast 
blocking / unblocking kinetics and strong voltage-depen-
dency [113, 196, 198, 229]. These properties have been 
characterized and confirmed by numerous groups using 
whole cell patch clamp recordings from primary cultures of 
hippocampal and cortical neurons as well as for NMDA re-
ceptors expressed heterologously in HEK-293 cells [29, 34, 
43, 154, 198-201, 259, 260]. How these biophysical proper-
ties account for the better therapeutic safety of memantine 
compared to other channel blockers such as (+)MK-801 and 
phencyclidine has been a matter of considerable debate and 
there are several theories. 
  Memantine and other well tolerated open channel block-
ers show much faster open channel blocking / unblocking 
kinetics than compounds burdened with negative psychotro-
pic effects such as (+)MK-801 or phencyclidine [28, 28, 44, 
196, 198, 229, 231]. The kinetics of (+)MK-801 and phency-
clidine are too slow to allow them to leave the channel upon 
depolarization, which is often reflected in apparently weaker 
functional voltage-dependency. These two parameters are 
directly related to affinity, with lower affinity compounds 
such as memantine showing faster kinetics and apparently 
stronger voltage-dependency, as reflected in an estimated 
value of around 0.8 [201]. The value describes the percent-
age of the trans-membrane field the drug experiences when 
blocking the NMDA receptor channel [196]. The unblocking 
rate of memantine in the continuous presence of this antago-
nist following depolarizing voltage-steps is very rapid and 
well within the time course of NMDA receptor-mediated 
EPSP.  
  Memantine blocks and unblocks open NMDA receptor 
channelswithdouble exponential kinetics. The amplitude and 
speed of the fast component of block increases with meman-56 Current Neuropharmacology, 2008, Vol. 6, No. 1 Rammes et al. 
tine concentration. In contrast, the speed of fast unblock re-
mains constant but its weight (relative to the slow compo-
nent) decreases with memantine concentration [29, 34, 77, 
259, 260]. Moreover, the predominant effect of depolariza-
tion is to increase dramatically the weight of the faster re-
covery time-constant [34, 77, 199]. These data indicate that 
memantine binds to at least two sites within the channel 
[259, 260]. 
Fast Agonist Concentration-Dependent Access to the Open 
Channel During Pathological Activation 
  It has been proposed that the ability of low affinity open 
channel blockers to gain rapid access to the NMDA receptor 
channel is important in determining their therapeutic safety 
in ischemia and epilepsy [44, 229, 231]. However, this hy-
pothesis alone cannot explain the better therapeutic profile of 
memantine in AD as, even if receptors were only blocked 
following pathological activation, most would then remain 
blocked in the continuous presence of memantine and there-
fore be unavailable for subsequent physiological activation - 
in the therapy of AD, memantine is continuously present at 
very stable steady-state concentrations due to its very long 
half life in humans. 
  It has further been suggested that memantine blocks 
NMDA receptor channels in an agonist concentration-depen-
dent manner i.e. the more agonist, the more equilibrium 
blockade [152]. This assumption is supported neither by the 
blocking model proposed by [29] nor by our own recent un-
published data which highlight, for us, the technical prob-
lems in performing such studies [86]. At very low agonist 
concentrations, the open channel probability is very much 
reduced and open channel blockers take much longer to ac-
cess and to leave the open channel. As such, it seems most 
likely that memantine blockade only appeared to be less effi-
cacious at lower agonist concentrations in previous publica-
tions because it had not really reached equilibrium blockade. 
Fast, Voltage-Dependent Unblock from the Open Channel 
During Synaptic Activation–Basis for the Signal-to-Noise 
Hypothesis 
  Physiologically, NMDA receptors are transiently acti-
vated by mM concentrations of glutamate [48] following 
strong depolarization of the postsynaptic membrane, which 
rapidly relieves their voltage-dependent blockade by Mg
2+
[189] whereas, during pathological activation, NMDA recep-
tors are activated by lower concentrations of glutamate but 
for a much longer time [9, 19, 36, 87, 88, 177]. The voltage-
dependency of the divalent cation Mg
2+ is so pronounced 
that it also leaves the NMDA channel upon moderate depo-
larization under pathological conditions, i.e. in the presence 
of tonically mildly elevated glutamate levels and moderate 
membrane depolarization due to energy deficits. Although 
uncompetitive antagonists also block the NMDA receptor 
channel, high affinity compounds such as (+)MK-801 have 
much slower unblocking kinetics than Mg
2+ and less pro-
nounced functional voltage-dependency and are therefore 
unable to leave the channel within the time course of a nor-
mal NMDA receptor-mediated excitatory post-synaptic po-
tential. As a result, (+)MK-801 blocks both the pathological 
and physiological activation of NMDA receptors [196]. 
  We were the first to suggest that the combination of fast 
offset kinetics and strong voltage-dependency allows me-
mantine to rapidly leave the NMDA channel upon transient 
physiological activation by mM concentrations of synaptic 
glutamate, but block the sustained activation by M concen-
trations of glutamate under moderate pathological conditions 
[198, 200, 201]. This hypothesis is further supported by the 
fact that, although the slower component of offset kinetic at 
near resting membrane potentials and room temperature is 
still too slow to allow synaptic activation - i.e., around 5 sec-
onds, the relief of blockade in the continuous presence of 
memantine upon depolarization is much faster due to an in-
crease in the weight of the faster recovery time-constant [34, 
77, 259, 260]. These kinetics are almost certainly even faster 
in vivo due to higher temperatures [57]. Furthermore, the rate 
of recovery from memantine blockade is dependent on the 
open probability of NMDA channels [43, 197] and therefore 
would be faster in the presence of higher, synaptic concen-
trations of glutamate [48]. 
  Given the crucial role of NMDA receptor synaptic activa-
tion in neuronal plasticity, simplistic interpretation of the 
observation that a NMDA receptor antagonist such as me-
mantine can improve cognition and neuronal plasticity under 
pathological conditions might seem to be paradoxical. It 
should, however, be stressed that divalent cation Mg
2+ is an 
endogenous NMDA receptor channel blocker and its absence 
leads both to an impairment in neuronal plasticity [49, 74] 
and neuronal death [81]. Any dysfunction of postsynaptic 
neurons leading to weakened blockade by Mg
2+, e.g. due to 
partial depolarization as a consequence of an energy deficit, 
may also trigger prolonged Ca
2+ influx and structural (neu-
ronal loss) deficits [54, 230]. Because memantine is more 
potent and slightly less voltage-dependent than Mg
2+ due to 
its simple monovalent charge, it may thus serve as a more 
effective surrogate for Mg
2+ [198]. As a result of its some-
what less pronounced functional voltage-dependency, me-
mantine is more effective than Mg
2+ in blocking tonic patho-
logical activation of NMDA receptors at moderately depolar-
ized membrane potentials. However, following strong synap-
tic activation, memantine, like Mg
2+, can leave the NMDA 
receptor channel with voltage-dependent, fast unblocking 
kinetics. In turn, memantine not only suppresses tonic patho-
logical synaptic “noise” but also allows the relevant physio-
logical synaptic signal to be detected. This provides both 
neuroprotection and symptomatic restoration of synaptic 
plasticity by one and the same mechanism [54, 196]. An-
tagonists that have “too high” affinity for the channel or “too 
little” functional voltage-dependence, such as dizocilpine 
((+)MK-801), thus produce numerous side effects, since they 
essentially act as an irreversible plug of the NMDA receptor 
channel and block both pathological and physiological func-
tion.  
Partial Untrapping 
  Another theory to explain the better therapeutic tolerabil-
ity of memantine was proposed in a seminal paper by [29] 
and supported by data from [169, 259] (see [113] for re-
view). Their data indicate that memantine and amantadine 
appear to have a lesser tendency to be trapped in NMDA 
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difference was attributed to the ability of channel blockers to 
increase the affinity of NMDA receptors for agonist and the 
faster kinetics of the amino-adamantanes. Receptors blocked 
by memantine retain agonist and thereby open and release 
memantine following removal of both agonist and meman-
tine from the extracellular solution - see also [43]. This par-
tial untrapping was reported to be less pronounced for higher 
affinity compounds as their slower unblocking kinetics do 
not allow them to leave the channel quickly enough follow-
ing agonist removal. 
  Recently, Dr. Johnson’s group provided more data char-
acterizing the mechanism underlying partial trapping of me-
mantine but not ketamine in the NMDA receptor channel 
[113, 129]. Their most recent data are also consistent with a 
model in which there are two binding sites for memantine, a 
deep site inside of the external gate that allows trapping and 
a shallow site outside the gate that does not (see also [32]. 
Ketamine only binds to the deep site [113, 129]). 
  This same group [29] proposed that partial trapping may 
underlie the better therapeutic profile of memantine, as a 
proportion of channels - around 15 to 20% - would always 
unblock in the absence of agonist and thereby be available 
for subsequent physiological activation. In other words, the 
antagonism by memantine is like that of a low intrinsic activ-
ity partial agonist in that it does not cause 100% blockade of 
NMDA receptors. However, although this theory can be used 
to explain the therapeutic tolerability of memantine, it pro-
vides no MOA for the symptomatic effects on cognition ob-
served in AD patients. 
Channel Blocking Site 
  Several studies indicate that memantine and Mg
2+ block 
at the same or similar channel site as they are mutually ex-
clusive - as evidenced by the kinetics of unblock in the pres-
ence of both [44, 259]. Moreover, the potency of memantine 
was observed to be reduced 20 fold by mutations at the N-
site (N598Q) of the M2 trans-membrane segment in NR1 
subunits and 30- to 100- fold by double mutations (W593L/ 
N598Q) within the channel-forming domain. Double muta-
tions at the equivalent L- (L577W) and Q/R-sites (Q582T) in 
GluR1 receptors permitted open channel blockade of AMPA 
receptors by memantine (IC50 at -70 mV = 1.3 M, =0.75) 
[71]. In this study on human NR1/NR2A receptors expressed 
in Xenopus oocytes, memantine blocked normal receptors in 
a strongly voltage-dependent manner (IC50 at -80 mV = 0.3 
M,= 0.77; [71]).  
  In a more recent study in Xenopus oocytes, memantine 
blocked rat NR1a/2B receptors with an IC50 of 0.46 M at –
70 mV. The effects of memantine were strongly voltage-
dependent with a  value of 0.89 and a Kd(0) value of 7.1 
M. Mutations at the critical asparagine residues in the M2 
loop of NR1 and NR2B and at a tryptophan residue in M2 of 
NR2B reduced blocking by MK-801, memantine and TB-3-
4. In contrast, many mutations at residues in the pre-M1, M1, 
M3, post-M3 and post-M4 regions reduced blocking by MK-
801 and TB-3-4, but had no effect on the block by meman-
tine [116]. 
  We attempted to verify the common channel blocking 
locus proposed for memantine and Mg
2+ using channel muta-
tions at the N-sites of NR1 and NR2 receptor subunits [202]. 
N598G mutations at the N-site of the M2 trans-membrane 
segment in NR1a subunits and N595G or N596G mutations 
in the NR2A subunit had little or no effect on the potency of 
memantine. These same mutations had pronounced effects 
on the potency of Mg
2+ and double mutations may have even 
apparently permitted permeation of this divalent cation [117, 
299, 300]. This contrasts with the N598Q mutation data [71] 
which decreased the potency of memantine but had little or 
no effect on Mg
2+ voltage-dependent block [237, 299]. These 
differences gave important insights into differences in the 
mechanism of channel blockade by memantine and Mg
2+.
  All mutations in our own internal study replaced aspar-
agine residues with short “naked” residues. These sites are 
known to act as channel binding sites for Mg
2+ and these 
mutations, as expected, reduced the potency of Mg
2+ [299]. 
In contrast, they did not have any effect on the potency of 
memantine, indicating that memantine can still plug the wid-
ened pore (from 0.55 to 0.7 nm). The N598Q mutation used 
by [71] replaces an asparagine with a longer glutamine resi-
due. This could reduce the pore diameter and thereby prevent 
memantine from penetrating so deeply whilst having little 
effect on the Mg
2+ binding site. This difference indicates 
that, in contrast to Mg
2+, the channel block by memantine is 
determined largely by the size of the channel pore.  
  In contrast to glycine site NMDA receptor antagonists, 
memantine (12 M) did not inhibit NR1/NR3 “excitatory 
glycine” receptors expressed in Xenopus oocytes [42]. 
In Vivo NMDA Receptor Antagonism 
  Memantine selectively reduced responses of single spinal 
neurones to micro-iontophoretic application of NMDA with 
an ID50 of around 2 mg/kg i.v. in anaesthetised rats [184] and 
inhibited NMDA-induced convulsions in mice with an ID50
of 4.6 mg/kg i.p. [27, 201]. In a more recent study, meman-
tine protected against NMDA-induced convulsions (ED50 2.9 
mg/kg) at doses that were 7-, 8- to 18-fold lower than those 
producing effects on MK-801 discrimination, ataxia or lo-
comotion respectively [85]. In rats, convulsions produced by 
i.c.v. injection of NMDA were inhibited by memantine with 
an IC50 of 9.7 mg/kg [27]. Memantine was also potent with 
an ID50 of 2.7 mg/kg against NMDA-induced damage of 
cholinergic neurons in the Nucleus Basalis of Meynert 
(NBM) [288]. 
  Initial data indicated that much higher doses of meman-
tine were required to block responses of spinal neurones to 
micro-iontopho-retic NMDA (ID50 of 26 mg/kg i.v.) [100]. 
However, more recent data from the same group [114, 167], 
showedmemantinetobemorepotentwhenthecontrol NMDA 
responses were of low intensity. Memantine (10  mg/kg), 
ketamine (2 mg/kg) and (+)MK-801 (0.1 mg/kg i.v.) reduced 
responses to similar levels (15-25% of control). Memantine 
was less effective against stronger intensity responses of the 
same neurons and this difference was reflected in a strong 
correlation between ID50 and control firing rate. (+)MK-801 
was equieffective and ketamine was somewhat less effective 
against stronger responses. This difference likely reflected 
the stronger voltage-dependency of memantine and probably 
underlies the differences observed in the in vivo potencies of 
memantine in different laboratories (see [100, 184]). 58 Current Neuropharmacology, 2008, Vol. 6, No. 1 Rammes et al. 
5-HT3Receptors
 5-HT3 receptors are also ligand-gated ionotropic recep-
tors permeable for monovalent cations. 5-HT3 receptors not 
only have a high density in the area postrema but also in the 
hippocampal and amygdala regions of the limbic system. 
The immediate consequence of neuronal depolarization re-
sulting from 5-HT3 receptor activation is neurotransmitter 
release,particularlydopamineinmesolimbicpathways, which 
suggests a potentially important role for this receptor system 
in neuronal circuitry involved in drug abuse. As such, 5-HT3
receptor antagonists may, in addition to their well character-
ized efficacy in emesis and irritable bowel syndrome, also be 
useful in the treatment of drug abuse, anxiety, cognitive defi-
cits and depression [51,90,93, 128, 155, 155, 166, 210, 210]. 
  We investigated the effects of memantine, amantadine 
and neramexane on human 5-HT3 receptors stably expressed 
in HEK-293 cells and on native murine 5-HT3 receptors in 
the N1E-115 cell line [220]. Our results clearly showed that 
memantine, neramexane and other amino-alkyl-cyclohexanes 
are, in addition to their well characterized action as uncom-
petitive NMDA receptor antagonists, also antagonists of 5-
HT3 receptors. These effects were seen at concentrations 
similar to those required for uncompetitive antagonistic ef-
fects at NMDA receptors. These uncompetitive NMDA re-
ceptor antagonists had similar effects on 5-HT3 receptors to 
those previously reported for different classes of anti-depres-
sants [69] and antipsychotics [218] i.e., they probably an-
tagonized responses by inducing desensitization. The effects 
were not voltage- or use-dependent and there was no evi-
dence for open channel blockade. Importantly, similar effects 
were not seen with ketamine. 
  Moreover, it seemed possible that combined antagonistic 
effects at NMDA and 5-HT3 receptors by e.g. memantine 
would lead to positive synergistic effects, which could con-
tribute to the therapeutic safety and efficacy in AD by in-
creasing desired effects - cognitive enhancement [294] and 
antidepressive activity [69, 70, 293] whilst further reducing 
possible negative effects of NMDA receptor antagonism e.g. 
by reducing mesolimbic dopamine hyperactivity [93]. 
  However, antagonism of the 5-HT3 receptor does not 
seem to play a major role for the good tolerability of meman-
tine versus e.g. ketamine in vivo in rats. Thus, recent data 
indicate that 5-HT3 receptor blockade with MDL 72222 (0.3-
3 mg/kg) does not ameliorate the behavioural deficits (ataxia, 
stereotypes, deficits in prepulse inhibition and learning) of 
ketamine [127] - an NMDA receptor antagonist that does not 
itself block 5-HT3 receptors [220]. However, these authors 
proposed that 5-HT3 antagonism might still contribute to 
certain effects, such as the antidepressant-like actions [127]. 
Memantine (5 mg/kg) had no anti-emetic effect in cisplatin-
treated ferrets, in contrast to treatment with odansetron or 
granisetron [146], indicating a lack of 5-HT3 receptor block-
ade after a behaviorally active dose. One caveat here, how-
ever, is that we have little information on the pharmacokinet-
ics of memantine in this species. 
Neuronal Nicotinic Receptors 
  Changes in neuronal nicotinic receptors have been impli-
cated in a number of diseases [163, 208, 238, 244, 287]. 
These include AD, Parkinson's disease, Tourette´s syndrome, 
schizophrenia, drug abuse and pain. Based on the observa-
tion that the nicotinic agonist nicotine itself seems to have 
beneficial effects, most drug development effort so far has 
aimed at the discovery of selective nicotinic agonists, espe-
cially for 42 receptors. On the other hand, it is unclear 
whether the effects of nicotinic agonists in e.g. Tourette´s 
syndrome and schizophrenia are due to the activation or in-
activation / desensitization of neuronal nicotinic receptors - 
e.g. meca-mylamine is also active [239]. 
  The effects of agonists on neuronal nicotinic receptors 
are strongly dependent on the exposure period. Rapid re-
versible desensitization occurs in milliseconds, rundown 
occurs in seconds, irreversible inactivation of 4ß2 and 7
containing receptors occurs in hours and their upregulation 
occurs within days. In other words, the effects of nicotinic 
"agonists" may in fact be due to partial agonism, inactivation 
and/or desensitization and adaptive changes in the expression 
of neuronal nicotinic receptors. In turn, moderate concentra-
tions of neuronal nicotinic receptor channel blockers could 
produce the same effects as reported for nicotinic agonists in 
the above mentioned indications. This is especially likely for 
7 receptors, which show complete desensitization. 
  As an example, there is considerable evidence that nico-
tinic antagonists might produce similar effects to agonist in 
animal models of learning. Thus, under certain conditions, 
both nicotine and the nicotinic antagonist mecamylamine 
improve learning [148]. Although nicotine improves mem-
ory, 2-deficient mice actually show improved learning and 
show no additional beneficial effects of nicotine [209]. In 
vitro experiments also indicate that both the activation of 
non-7 nAChRs and inactivation of 7 nAChRs contribute 
to LTP induction [80]. Moreover, chronic nicotine-mediated 
facilitation of LTP induction was probably due to chronic 
nicotine-induced desensitization of 7 nAChRs [80]. Simi-
larly, chronic treatment with both nicotine and mecamy-
lamine increased nicotinic receptor number [205, 206] and 
both nicotine and mecamylamine enhanced haloperidol-
induced catalepsy [149]. 
  Memantine has been found to inhibit 42 responses 
with an IC50=6.6 or 11.3 M [37, 63], however, this level is 
probably too high to be of real therapeutic significance. In 
line with this, in vivo memantine at 10 mg/kg had only mild 
effect on nicotine discrimination [30, 305] mediated by 
42receptors [162] at doses that also affected saline re-
sponding indicating lack of selectivity. The reported potency 
of memantine at 7 receptors varies considerably, from 0.33-
1.68 M seen in rat receptors [11, 63], to 5M observed in 
human receptors [165], the latter finding making it seem less 
likely to be of therapeutic relevance for AD patients. Moreo-
ver, even in rats, recent studies (Nagel, personal communica-
tion) indicate that at 5-10 mg/kg, memantine does not pro-
duce changes in dopamine levels in the striatum that would 
be consistent with the blockade of 7 receptors [222] – in 
fact, memantine caused an increased release of dopamine, 
not a decrease as would be expected for an 7 antagonist. 
These results were confirmed by a micro-dialysis study 
showing that memantine (20mg/kg) resulted in significant 
increases in extracellular dopamine, norepinephrine and their 
metabolites in cortical regions [251]. Pharmacodynamics of Memantine  Current Neuropharmacology, 2008, Vol. 6, No. 1  59
  Although memantine blocks 9/10 nicotinic receptors 
with similar affinity to NMDA [191], these receptors show a 
very discrete distribution e.g. in cochlear hair cells and this 
action is therefore highly unlikely to be responsible for 
therapeutic effects of memantine on symptoms in AD [65, 
119]. In agreement with published data [191], memantine 
blocked 9/10 receptors expressed in Xenopus oocytes at –
70 mV with an IC50 of 1.20 M and in a weakly voltage-
dependent manner [64]. 
  Interestingly, the effect of memantine on all tested “neu-
ronal”nicotinicreceptorswasonlyweakly voltage-dependent, 
as is the case for 5-HT3 receptors (see above), which often 
share a common pharmacology with neuronal nicotinic re-
ceptors and implies a site of action, which is not deep inside 
the channel. 
Summary 
  Taken together with data reviewed previously [55, 124], 
it seems clear that NMDA receptor antagonism is the pri-
mary mechanism of action of therapeutic relevance for me-
mantine although additional effects at 5-HT3 receptors and 
neuronal nicotinic receptors may be supportive for therapeu-
tic tolerability. The effects on NMDA are far more consistent 
across species i.e., human and rat, whereas effects on neu-
ronal nicotinic receptors seem to be species-dependent and 
findings specific for neuronal nicotinic receptors from rodent 
studies may bear little or no relevance for the human thera-
peutic situation. Additional support for NMDA receptor an-
tagonism in vivo at therapeutically-relevant doses is provided 
by its strong neuroprotective activity in animal models dis-
cussed later. 
PRIMARY PHARMACODYNAMICS 
  AD is the most common form of dementia, the other two 
major forms being vascular dementia (VD) and mixed Alz-
heimer's/vasculardementia(AD/VD). Acetylcholine esterase 
inhibitors (AChEi) aim to improve cognitive and sympto-
matic behavioral symptoms and thereby, the quality of life 
for the patients / caregiver. NMDA-receptor-mediated glu-
tamate excitotoxicity is hypothesized to play a major role in 
both the symptoms and pathomechanism of this disease. 
Memantine is a clinically proven effective therapy for symp-
tomatic treatment of Alzheimer's disease [224, 271, 297]. 
The preclinical data discussed below provide reason to be-
lieve that memantine, in addition to symptomatic treatment 
for AD, could also be an effective disease-modifying agent 
in this devastating disorder. 
Alzheimer’s Disease 
Symptomatic Effects 
  Removal or reduction of magnesium in hippocampal 
slices causes deficits in LTP [49] and this could be reversed 
by memantine with a bell-shaped concentration-response 
curve with near complete reversal of this deficit by therapeu-
tically-relevant concentrations [74]. Similarly, in hippocam-
pal slices, low concentrations of NMDA also caused a reduc-
tion of LTP induction / expression in the CA1 region [109, 
304]. This deficit was also reversed by memantine at a con-
centration of 1 HM [304]. In support of these effects of me-
mantine, in knockout mice lacking the glutamate transporter 
GLT-1, LTP was also impaired in the hippocampal CA1 
region in vitro. When tetanic stimulation was applied in the 
presence of a very low concentration of the competitive 
NMDA receptor antagonist AP5 (0.5 M), the impairment 
was reversed [118]. 
  Memantine (20 mg/kg/day, 7–13 days after lesioning and 
4 days before training) caused a symptomatic improvement 
of spatial learning of rats in the radial maze following lesions 
of the entorhinal cortex with quinolinic acid. These memory 
improving effects of memantine were not related to changes 
in brain NGF content or choline acetyltransferase (ChAT) 
activity [143]. 
  Memantine was confirmed to improve learning in a radial 
water maze task where rats were given 4 trials and then 
tested 1 h later and 1 day later. Only one arm was reinforced 
(safe platform) and the start on each trial was from a differ-
ent position. Memantine (at 5 and 7.5 but not 2.5 mg/kg), 
administered 30 min before day 1 training, did not affect 
performance on day 1 but enhanced learning (decreased the 
number of errors) 24 h later. This result was explained by 
tempering over-activation of NMDA receptors resulting 
from massive glutamate release in stressful conditions such 
as in the water maze [310]. Withdrawal from chronic (6 
month) alcohol ingestion produced robust learning deficits in 
rats in the Morris water maze. Treatment with memantine 
starting at the beginning of the withdrawal phase (20 mg/kg 
bolus followed by 1 mg/kg every 12 h for 4 weeks) resulted 
in a complete reversal of these behavioral impairments [158]. 
  Memantine 10 mg/kg re-instated experience dependent 
place field neuronal firing field expansion in aged rats. This 
effect was claimed to be due to a dampening of Ca
2+ over-
load by memantine, which fits perfectly to the signal-to-
noise hypothesis [39]. 
  Even in much lower species, memantine has been 
claimed to improve learning by reversing noise at glutama-
tergic synapses. The glutamate transporter inhibitor (L-trans-
2,4-PDC)-induced olfactory amnesia in honeybees (Apis 
mellifera) was 'rescued' by memantine (1-10mM, 1l per 
bee) injected either before training, or before testing, sug-
gesting that memantine restores memory recall rather than 
memory formation or storage. When injected alone, meman-
tine also had a mild facilitating effect on memory. In con-
trast, MK-801 also impaired memory in all tests [254]. 
  Memantine (30 mg/kg/day; p.o.) for 2-3 weeks signifi-
cantly improved the acquisition of the water maze task in 
APP/PS1 mice without affecting swimming speed. Meman-
tine affected neither locomotor activity nor aggressive be-
havior in transgenic or wild type mice. These data indicate 
that memantine improves hippocampus-based spatial learn-
ing in a transgenic murine model of AD without producing 
non-specific effects on locomotion/exploratory activity 
[174]. 
  Low doses of memantine (2 mg/kg i.p. daily for 1 week) 
had mild symptomatic effects on cognition in the Morris 
water maze in APP23 mice, especially during the probe trial. 
Higher doses of 10 mg/kg were ineffective. This study com-
pared memantine to AChE inhibitors, where a consistent 
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were shown to be effective, but higher doses were not. How-
ever, the difference in doses of the AChE inhibitors was two-
fold, but for memantine it was 5-fold. Biphasic effects on 
cognition / synaptic plasticity are well known for memantine 
and it seems likely that better effects would have been seen 
had 5 mg/kg also been tested [277]. 
 Zhao  et al. discussed in vitro data to support the benefi-
cial actions of galanthamine and memantine combinations 
[309].Memantinewasreportedtoblock extrasynaptic NMDA 
receptors (IC50 = 22 nM) 100 times more potently than the 
synaptic NMDA receptors at negative membrane potentials 
(IC50 = 2.5 M) and the block of both types of NMDA re-
ceptor was strongly voltage-dependent. Galanthamine (1M)
potentiated NMDA receptors in a non voltage-dependent 
manner. Co-application of memantine with galanthamine 
prevented the galanthamine potentiation and the activation of 
extrasynaptic NMDA receptors, but membrane depolariza-
tion revealed the galanthamine potentiation of proposed syn-
aptic receptors. The authors therefore hypothesized that, in 
the presence of both drugs, cell death is expected to be pre-
vented by memantine near the resting potential, while 
NMDA-mediated synaptic transmission would be further 
potentiated by galanthamine. These results were claimed to 
provide an in vitro basis for the beneficial actions of gal-
anthamine and memantine combinations [309]. 
  It has been shown in vitro that memantine does not at-
tenuate the effects of AChE inhibitors used clinically in AD 
such as donepezil, tacrine or galanthamine, in contrast to 
clear attenuation of irreversible inhibition by DFP [291]. In 
an in vivo study, memantine (10mg/kg) did not inhibit AChE 
in any brain areas and did not interact with donepezil and 
rivastigmine [92]. This lack of negative interaction is also 
supported by recent studies investigating AChE activity in 
man and in clinical studies focusing on symptomatic effects 
[59a, 67, 207]. 
Neuroprotection 
Introduction
 Wenk  et al. have published many studies indicating that 
memantine is neuroprotective against various insults to the 
cholinergic NBM. These effects were expressed both in his-
tological and functional terms [290]. Inflammatory changes 
are closely related to the cognitive and neuropathological 
manifestations of AD [3, 4]. Infusion with lipopolysaccha-
ride(LPS, a component of Gram-negative bacteria cell walls) 
led to a massive inflammatory reaction followed by cell loss 
in the NBM. Memantine, (20 mg/kg/day) infused s.c. in par-
allel to LPS, provided significant protection of NBM neu-
rons [290, 292, 296].  
  In conformation of these positive findings, following 
infusion of ibotenic acid into the NBM of rats, acute admini-
stration of memantine (10 mg/kg, i.p.) blocked the increase 
of astrocytes and microglia activation in the cortex [2]. In a 
recent study from Wenk´s group, memantine did not prevent 
the neurotoxic effects of TNF-alpha on cholinergic neurons 
[289]. This, taken together with the previous studies de-
scribed above, indicates that NMDA receptors are involved 
in neurodegeneration resulting from inflammation produced 
by LPS, but not TNF-alpha infusion. In this study, TNF-
alpha was infused for a prolonged time, which contrasts to 
the short lasting increase of this cytokine following treatment 
with LPS as in the previous work.  
  Systemic oral administration of memantine 2 mg/kg daily 
for 13 days, to rats with chronic partial AF64A-induced dep-
rivation of cholinergic functions, improved their learning in a 
Morris water maze [14, 147]. This effect of memantine had a 
longer duration of action than the acetylcholine esterase 
(AChE) inhibitor donepezil [147]. Importantly, memantine 
shows no negative interaction in vitro and in vivo with AChE 
inhibitors used in the treatment of AD [67, 207, 291]. 
  Memantine (20 mg/kg/day) was able to prevent and re-
verse the occurrence of learning and spatial memory deficits 
after cortical devascularization injury (inducing cortical cho-
linergic terminal loss and retrograde degeneration of the cho-
linergic projections from NBM) in rats [233]. 
  In rats chronically infused into the 4th ventricle for 28 
days with LPS (via osmotic minipump), there was a region-
selective microglia activation, impaired hippocampal-depen-
dent memory and altered behaviorally-induced expression of 
the immediate early gene Arc [234]. A therapeutically rele-
vant dose of memantine (10 mg/kg/day s.c. for 28 days) was 
also able to restore Arc gene expression to normal levels, 
reduce the number of activated microglia an expression of 
brain inflammation - and ameliorate spatial memory impair-
ments [234]. These results confirm the role of dynamic 
changes in Arc expression in neuronal plasticity and demon-
strate the ability of memantine to reinstate the dynamic bal-
ance of cellular processes that were disturbed by chronic 
brain inflammation. 
-Amyloid
  Chronic s.c. osmotic pump infusion of memantine 
(steady-state plasma concentrations of 2.34 M, for 9 days) 
reduced local neuronal cell loss produced by intra-hippo-
campal injection of A1-40 [172]. Recently, the same group 
reported inhibition of apoptosis induced by A1-40 infused in 
the hippocampus by memantine [15, 173]. 
  Neuroprotective effects of memantine against Aß toxicity 
have also been shown in functional terms. Indeed, it was 
recently shown that infusion of memantine prevented the 
development of delayed non-matching to sample lever press-
ing task impairments produced by infusion of A1-40 in rats 
[301]. Rats injected in the hippocampus with aggregated 
Aß1-40 (4 g/l), and two days later, with the NMDA recep-
tor agonist ibotenic acid (0.3 g/0.5  l) showed learning 
deficits in the Morris water maze task and neuronal damage 
in the hippocampus from 5 to 6 weeks after the injection 
[180]. Memantine (10, 20 mg/kg/day s.c. infusion for 6 
weeks starting 24 h before the Aß1-40 injection) caused a sig-
nificant inhibition of the learning deficits, but a lower dose 
of memantine (5 mg/kg/day) and both tested doses of MK-
801 (0.312, 0.624 mg/kg/day) did not have significant ef-
fects. In naive rats, MK-801 produced a significant learning 
impairment in the water maze task at a dose of 0.624 
mg/kg/day, whilst memantine (20 mg/kg/day s.c. infusion) 
did not [180]. 
  In a murine transgenic model of AD (APP23), meman-
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formance seen in vehicle-treated animals. This “disease-
modifying” effect was observed three weeks after treatment 
termination, an important control in such functional studies 
supporting neuroprotective effects in the absence of interfer-
ence from potential symptomatic effects in the continuous 
presence of drug [278]. Also, transgenic mice (APPswe) 
treated chronically with memantine showed lower levels of 
membrane-bound APP [275]. 
  In studies in cultured human neuroblastoma (SK-N-SH) 
cells, treatment with memantine for 24 to 48 hours provided 
evidence that the drug may decrease disturbed APP process-
ing [142]. Memantine treatment of cultured human neuro-
blastoma cells and primary fetal rat cortical neurons, albeit 
for a longer duration of 12 days, also decreased levels of 
A1-40 starting at a therapeutically relevant concentration of 1 
M [142]. 
 Memantine  (1M), APV (10 M) as well as soluble tu-
mor necrosis factor alpha (TNF) receptor protected neurons 
fromAß1-42stimulationmicroglial-conditionedmedia-induced 
toxicity, implicating the excitatory neurotransmitter gluta-
mate and the pro-inflammatory cytokine TNF as effectors 
of microglial-stimulated death [73]. Interestingly, in vitro,
brief exposure of cultured cortical neurons to memantine (1-
20 M), which would produce only a transient block of 
NMDA receptors, inhibited the toxicity of NMDA for up to 
48 hours with an IC50 of around 5M [272]. In the same 
study, a high concentration of MK-801 (1M) provided 
long-term protection against toxicity due to NMDA, AMPA, 
staurospo-rine, etoposide, hypoxia and Aß1-40, applied 48 
hours later, but the relevance of this for memantine with re-
gard to chronic therapy in AD remains to be investigated 
[272]. 
  Chronic exposure of hippocampal cultures to soluble Aß 
oligomers induced reactive oxygen species and produced 
abnormal spine morphology and a decrease in their density. 
Subsequent consequences of this, such as synaptic deteriora-
tion including loss of the synaptic spine cytoskeletal protein 
debrin, were completely prevented by memantine (5-10 M)
[123, 141]. 
 Memantine  (1-10  M) did not protect against Aß1-42 tox-
icity in cultured rat septal cholinergic neurons, but this is not 
surprising, as these neurons themselves are relatively resis-
tant to NMDA toxicity [122]. 
Tau
  Overexpression of human tau and of some of its N-
terminal fragments in primary neuronal cultures leads to an 
NMDA receptor-mediated, caspase-independent pathway 
that was completely prevented by treatment with memantine 
(10 M) [7]. The authors proposed that “death” signalling 
likely originates from stimulation of extrasynaptic NR2B 
subunit-containing NMDA receptors and sustained phos-
phorylation of extracellular-regulated kinases 1 and 2. 
Moreover, NMDA receptor involvement causes the fatal 
activation of calpain, which, in turn, degrades tau protein 
into a 17-kDa peptide and possibly other highly toxic N-
terminal peptides. 
  The activity of protein phosphatase (PP)-2A, which regu-
lates tau phosphorylation, is compromised in the AD brain. 
Memantine (1M) reduced phosphorylation of tau (ser262) 
and prevented neurotoxicity produced by okadaic acid in a 
rat hippocampal slice preparation [150]. Transient transfec-
tion of PC12 cells with inhibitor-2 of PP2A (I(2)(PP2A)) 
also causes abnormal hyperphosphorylation of tau at Ser396/ 
Ser404 and Ser262/Ser356. Memantine (10 M) inhibited 
this abnormal phosphorylation of tau and cell death and pre-
vented the I(2)(PP2A)-induced inhibition of PP2A activity 
with no effect on basal activity [47]. It is not clear whether 
this effect is solely due to NMDA antagonism, since a com-
petitive antagonist and an antagonist acting at the glycine site 
of the NMDA receptor were ineffective, at least at the con-
centrations used (ibid.). 
  It has also recently been shown that after chronic treat-
ment of AD patients with memantine for 12 months, the CSF 
levels of phosphorylated tau decrease while non-phosphory-
lated tau and Aß remain unchanged [59b]. 
  Recently, further insights into the possible MOA for this 
effect became available. It was reported that memantine 
caused an increase in vivo in phosphorylation of GSK-3, 
which inhibits its function and could thereby reduce phos-
phorylation of presenilin 1, 2 and tau [58], but it is very un-
clear whether this has anything to do with NMDA receptor 
blockade due to the very high dose used (50 mg/kg).  
  Taken together, these findings suggest that memantine 
might also be useful for the treatment of related tauopathies. 
Summary of Neuroprotection in AD
  On the basis of the animal experiments detailed here and 
in many previous studies, memantine at therapeutic doses in 
AD patients [224, 271] could provide inhibition of disease 
progression due to its neuroprotective properties [196].  
Neurorestorative Effect 
  Memantine enhanced neurogenesis at therapeutically 
relevant concentrations in cortical cultures in vitro (the best 
effects were seen at 1 M, with 140% of control neurogene-
sis) and in the DG and forebrain sub-ventricular zone in vivo
(7.5 mg/kg p.o. once daily for 14 days, around 126% of con-
trol neurogenesis) [112]. However, in another study, al-
though acute treatment of rats with memantine (20 mg/kg) 
also led to an increase in neurogenesis in the hippocampus, 
this effect disappeared after 7 days. Moreover, in contrast to 
acute treatment, chronic infusion of memantine with mini-
pumps (20 mg/kg/d) failed to increase neurogenesis [253]. 
SECONDARY PHARMACODYNAMICS 
  As a reminder, this review is intended to provide an up-
date on preclinical studies on the pharmacodynamics of me-
mantine. For most studies prior to 1999, the reader is re-
ferred to a previous review [196]. Apart from studies which 
are supportive of the neuroprotective effects of memantine, 
new data on secondary pharmacodynamic effects are pre-
sented with no ordered preference for validity or relevance. 
Activity in Models of Neurodegenerative Conditions 
Introduction 
  It is widely accepted that NMDA receptor antagonists 
have neuroprotective activity in a variety of animal models 62 Current Neuropharmacology, 2008, Vol. 6, No. 1 Rammes et al. 
of acute excitotoxicity. In acute ischemia, they are generally 
more active in models of focal, rather than global ischemia, 
when confounding factors such as changes in body tempera-
ture are taken into account [35]. Concerning the acute neuro-
protective effects of memantine, the literature before 1999 
has been reviewed in detail by [196]. For the sake of com-
pleteness, we included this information in a somewhat ab-
breviated form to provide a preface for new studies. 
General Neuroprotective Activity 
In Vitro
  Numerous studies indicate that memantine protects 
against the toxic effects of exogenous NMDA receptor ago-
nist in cultured neurones with an IC50 close to 1M [196]. 
More recently, memantine was shown to protect rat neurons 
in organotypic hippocampal slices from NMDA-induced 
excitotoxicity (IC50 around 1 M) and was similarly protec-
tive in cerebellar granule cell cultures when assessed as cell 
death with H-33342, but was less potent on viability assessed 
with MTT (IC50 around 10 M) [280]. In the same study, 
(+)MK-801 negatively interfered with neuronal migration 
after excitotoxic insult in cerebellar micro-explant cultures, 
since the directed movement of neurons is dependent on 
physiological NMDA receptor activity. In contrast, meman-
tine caused significant recovery from these deficits providing 
further evidence for the ability of memantine to differentiate 
between physiological and pathological activation of NMDA 
receptors [280]. 
  Memantine alone (0.05-2.0 M) concentration-depen-
dently attenuated staurosporine-induced caspase-3 activity 
and lactate dehydrogenase (LDH) release in hippocampal 
cultured neurons after 7 and 12 days in vitro but had no ef-
fect in control cultures. These effects of memantine were 
more pronounced in hippocampal cultures than in neocortical 
and striatal cultures, which can be explained by different 
expression patterns of NMDA receptor subtypes [111]. An-
other group claimed that a higher concentration of meman-
tine (10M) potentiated neuronal death caused by exposure 
to staurosporine (10-30 nM for 48 h) in cultured murine neo-
cortical neurons, but in their hands, caffeine 1 mM also ex-
acerbated this death, which somewhat questions the validity 
of the model used [257, 258]. 
  Memantine and (+)MK-801 blocked strong hypoxia / 
hypoglycemia-induced suppression of fEPSPs in rat hippo-
campal slices with EC50s of 14.1 and 0.53 M respectively 
[76]. Whereas memantine blocked this effect with a similar 
potency to at which it blocks the induction of LTP, (+)MK-
801 was four times less potent in this model than against 
LTP [77]. The calculated relative therapeutic indices (IC50
LTP over EC50 hypoxia / hypoglycaemia) for memantine and 
(+)MK-801 were 0.82 and 0.28, respectively. These results 
show that, even in a severe model of hypoxia / hypoglyce-
mia, moderate affinity channel blockers exhibit a better 
therapeutic index than high affinity channel blockers. The 
authors proposed that it is likely that in milder forms of pa-
thology, the observed differences in the therapeutic indices 
remain the same but the absolute values can be expected to 
be higher. Similarly, memantine (10 M) also reduced LDH  
release from hippocampal slices by 40% following 1 hour of 
oxygen glucose deprivation (OGD) plus reoxygenation for 3 
hours when treatment was started 30´ prior to OGD and con-
tinued for the duration of the study [261]. 
  Memantine also protected cultured cerebellar granule 
cells from apoptosis induced by OGD (IC50 around 10 M) 
or treatment with the mitochondrial toxin 1-methyl-4-
phenylpyridinium (MPP+) or nitric oxide (NO) donors (IC50
around 10 M) [280]. A very high concentration of meman-
tine (50M) blocked NMDA receptor currents and com-
pletely protected against 3hrs of OGD in a human embryonic 
teratocarcinoma cell line (NT2) that expresses NMDA recep-
tors (NR2B>BNR2C>NR1>NR2A) [83]. Unfortunately, 
lower concentrations were apparently not tested. 
  Memantine (i.p. 5-50 mg/kg; 4 h) markedly increased 
BDNF mRNA levels in the limbic cortex and this effect was 
more widespread and pronounced at higher doses [164]. The 
effects of memantine on BDNF mRNA were also reflected in 
changes in BDNF protein levels. Moreover, memantine in-
duced isoforms of the BDNF receptor trkB. The authors sug-
gested that the neuroprotective properties of memantine 
could be mediated by the increased endogenous production 
of BDNF in the brain. 
  Memantine was somewhat less effective in protecting 
against acute excitotoxic insult by 3-nitrophenol (3-NP) in 
cerebellar micro-explant cultures [280], but these experi-
ments were after acute 3-NP (0.5 mM) treatment c.f. treat-
ment with 3-NP (35 M) for 7-12 days in other studies more 
relevant for chronic excitotoxicity [115] - see below. Me-
mantine (10 M) reduced depolarization-induced superoxide 
radical formation in hippocampal slices following acute ex-
posure to high extracellular K
+ (50 mM). The block was less 
pronounced than that seen with MK-801 (1M), possibly 
due to the greater voltage-dependency of memantine and/or 
the very high concentration of MK-801 used [242]. Exposure 
of cultured cortical neurons to elevated extracellular K
+ con-
centrations (25 mM) induced membrane depolarization and 
an increase in action-potential firing that was associated with 
increased neuronal cell death following long-term treatment 
(15 DIV) [110]. This excitotoxicity was prevented by the 
continuous presence of an extremely high concentration of 
memantine (50M) but lower concentrations were not tested 
[110]. 
  In an organotypic hippocampal slice model with more 
relevance for the chronic, low level excitotoxicity proposed 
to occur in e.g. AD, memantine was protective with IC50 of 
c.a. 1-2 M against semi-chronic excitotoxicity (4-20 days) 
produced by low concentrations of 3-NP (35 M) as meas-
ured as changes in LDH release [115]. In this study, meman-
tine also reduced both the cytoskeletal damage and synaptic 
decline in a concentration-dependent manner. Phase contrast 
microscopy, propidium iodide fluorescence and cresyl violet 
staining confirmed memantine´s neuroprotective effects. 
Furthermore, the protected tissue exhibited normal neuronal 
density and morphology in major hippocampal subfields. 
  The toxic effects of the scrapie prion protein, PrP(Sc), 
and its peptide fragment, PrP106-126, can be blocked by 
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promising approach to prevent neuronal death in Creutzfeldt-
Jakob disease [179]. 
  The combination of 10 nM memantine and clenbuterol 
was also reported to be very effective against staurosporine 
toxicity in vitro, but it is very difficult to reconcile this con-
centration with the MOA as an NMDA receptor antagonist 
[52]. It is conceivable that this was a typo, and in fact me-
mantine 10 M was tested – see [55, 203]. 
In Vivo
  As noted above, acute ischemia models are generally of a 
severe nature and the doses of NMDA receptor antagonist 
required are therefore very high. It is likely that lower doses 
provide neuroprotection inhibiting the progression of chronic 
neurodegenerative disorders such as AD. 
  Chronic dietary intake of memantine (31 mg/kg/day) for 
14 days prevented death, convulsions and hippocampal dam-
age induced by i.c.v. quinolinic acid [120]. Memantine also 
significantly attenuated malonate-induced striatal lesions 
implicating utility in chronic neurodegenerative diseases 
associated with deficits in mitochondrial function [246]. 
  Rats infused i.c.v. with quinolinic acid alone showed 
clear learning deficits in the T-maze whilst those infused in 
parallel with memantine (20 mg/kg/day s.c.) were able to 
acquire the task normally [176]. Similarly, a decrease in cho-
line uptake sites (an indicator of the density of ACh termi-
nals potentially relevant for AD) was seen in the cortex of 
animals treated with quinolinic acid but not in those receiv-
ing additional treatment with memantine. In this context, it is 
important that infusion of this same dose of memantine in 
normal rats had no effect on T-maze learning or LTP in hip-
pocampal slices ex vivo [176]. 
Ischemic Tolerance
  It has been known for several years that under certain 
conditions, a short ischemic/hypoxic episode or pharmacol-
ogical blockade of mitochondrial oxidative processes [227a] 
can decrease the susceptibility of neuronal tissue to subse-
quent severe insult - a phenomenon called ischemic toler-
ance. This fact might be of particular clinical importance in 
situations where a danger of succeeding episodes after mod-
erate ischemic insult can be anticipated, such as in vascular 
dementia (VD) or combined AD / VD. 
  Memantine (5 mg/kg) did not inhibit ischemic tolerance 
to global ischemia in gerbils in vivo [62]. In fact, subchronic 
3 day infusion of memantine (30 mg/kg/day) significantly 
decreased neurodegeneration on its own and potentiated the 
neuroprotective effects of ischemic pre-conditioning [62]. In 
a similar manner, memantine (20 mg/kg/day for 3 days via
Alzet minipumps) did not block 3-NP (20 mg/kg i.p.) - in-
duced delayed ischemic tolerance in rat hippocampal slices
ex vivo [75]. In contrast, 3 days pre-treatment with a high 
dose of (+)MK-801 (2 mg/kg/day) tended to reduce ischemic 
tolerance following 3-NP preconditioning. 
  As such, although NMDA receptors do seem to be in-
volved in ischemic / chemical tolerance, semi-chronic pre-
treatment with therapeutically-relevant doses of memantine 
does not block this phenomenon [75]. 
Models of Acute Excitotoxicity 
Stroke
  The “real” effective acute neuroprotective doses / con-
centrations in almost all reported preclinical acute, focal and 
global ischemia models were always higher than, or similar 
to, those producing other behavioral effects regarded either 
as positive (chronic neuroprotective, anticataleptic, or anti-
nociceptive effects) or as side effects (amnesia, ataxia, 
stereotypy) [35, 40, 171, 196, 243]. This fits perfectly with 
the known voltage-dependency of memantine and assumed 
strong depolarization during such strong acute insults. These 
acute ischemia models have less direct quantitative relevance 
for judgement of potential neuroprotective activity that 
would be useful for the inhibition of progression of chronic 
neurodegenerative disorders such as AD but are still useful 
for qualitative comparison of neuroprotective efficacies / 
side effects of different classes of NMDA receptor antago-
nist [76].  
  Interestingly, there is one clinical study conducted on 140 
stroke patients showing a beneficial effect of memantine 
given i.v. at 20 mg/kg for 5 days following stroke [66].  
  In more recent preclinical reports, memantine (10 mg/kg) 
reduced neurological deficits and infarct volume when ap-
plied 15 minutes after three hours of middle coronary artery 
(MCA) occlusion in a temporary focal cerebral ischemia 
model [89]. In addition, memantine attenuated brain edema 
formation and BBB permeability. Additionally, memantine 
(20 mg/kg once daily i.p. for 3 days, first treatment started 
30 min after the induction of intracerebral hemorrhage - 
ICH) caused a 47% reduction of hemorrhage volume, cou-
pled with an inhibitory effect on the tissue plasminogen acti-
vator/urokinase plasminogen activator and matrix metallo-
proteinase-9 level in a rodent model of ICH (stereotaxic in-
trastriatal administration of type IV bacterial collagenase). 
This memantine treatment was also found to reduce inflam-
matory infiltration and apoptosis and was also determined to 
induce functional recovery after ICH [145].  
  Memantine (20 mg/kg i.p. 30 mins post infarct followed 
by 1 mg/kg b.i.d. for 48 hours) reduced infarct volumes (37 
mm
3 c.f. 81mm
3 for controls) in a photothrombotic model of 
ischemia / stroke [263]. In a similar treatment paradigm, 
memantine was also effective against 2 hours of MCA occlu-
sion in spontaneously hypertensive rats [45, 60, 285]. Even 
this apparently relatively high dose of memantine was re-
ported to have no negative effect on learning in the Morris 
maze whereas (+)MK-801 1 mg/kg blocked learning [262]. 
However, there were errors in the rationale for these experi-
ments – the memantine group was only on twice daily main-
tenance doses of 1 mg/kg (the necessity of which for the 
neuroprotective activity was not demonstrated) at the time of 
memory testing 72 hours after the high dose 20 mg/kg bolus 
which clearly, and not surprisingly, provided protection 
against the acute insult. 
  In 7-day-old newborn rats, memantine (20 mg/kg) had 
long term functional neuroprotective effects against learning 
deficits in the Morris maze when administered immediately 
following global hypoxic-ischemic brain injury and assessed 
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  In a rabbit acute embolic infarct model, bolus i.v. injec-
tions of memantine at 1 mg/kg and 10 mg/kg did not alter the 
P(50) value and memantine and a dose of 25 mg/kg was le-
thal (NB: P(50) value = the amount of microclots (in mg) 
that produce neurological dysfunction in 50% of a group of 
animals). However, slowly infused memantine (25 mg/kg 
over 60 mins) significantly and substantially increased the 
P(50) value even when started 60 min following emboliza-
tion. Memantine administered 180 min following emboliza-
tion also increased the P(50) value but the response was 
more variable [144]. 
  Memantine (5 mg/kg) showed no neuroprotection to 
mitigate cerebral injury after hypothermic circulatory arrest 
in a porcine model [227b]. 
TBI
  Memantine (10 and 20 mg/kg, i.p.) showed neuroprotec-
tion after traumatic brain injury (TBI) induced in adult rats 
with a controlled cortical impact device. TBI led to signifi-
cant neuronal death in the hippocampal CA2 and CA3 re-
gions (by 50 and 59%, respectively), by 7 days after the in-
jury. Treatment of rats with memantine immediately after the 
injury significantly prevented the neuronal loss in both CA2 
and CA3 regions [221]. Memantine (10 mg/kg, i.p. 15 min 
after trauma) also significantly reduced lipid peroxidation 
levels in a rat model of closed head trauma in rats [194].  
Models of Chronic Excitotoxicity 
  In a murine model of amyotrophic lateral sclerosis (ALS, 
SOD1(G93A) mice), memantine treatment (10 mg/kg b.i.d. 
s.c. starting on postnatal day 70 until end point) caused a 
significant, but very moderate delay in disease progression 
and also moderately increased the life span [283]. 
Glaucoma 
  In macaque monkeys, systemic treatment with meman-
tine 4 mg/kg/day p.o. for 16 months was both safe and effec-
tive for reduction of functional loss associated with experi-
mental glaucoma - argon laser treatment of the anterior 
chamber angle, whilst having no effect on intraocular pres-
sure (IOP). These functional effects were seen at 3 and 5 
months but not 16 months after an elevation of the intraocu-
lar pressure [95-97]. Moreover, histological measurements 
showed that this memantine treatment still promoted retinal 
ganglion cell (RGC) survival even at the 16 month observa-
tion period [96]. Furthermore, memantine improved tomo-
graphic measurements of nerve head topography taken at 3, 
5 and 10 months after an elevation of IOP. The same group 
and others [91, 97] could also show similar results in a rat 
model for experimental glaucoma, where systemic treatment 
with memantine (10 mg/kg/day) was associated with a sig-
nificant reduction in glaucoma-induced loss of retinal gan-
glion cells. 
  Memantine 5 mg/kg i.p. following optic nerve crush in 
rats caused a two-fold increase in compound action potential 
amplitude and a 1.7-fold increase in survival of RGCs re-
spectively, two weeks after injury [298]. Memantine (10 mg/ 
kg/day  via osmotic minipumps for three weeks) reduced 
ganglion cell loss to 12% when applied immediately after 
insult in a chronic ocular hypertension model induced by 
laser photocoagulation of episcleral and limbal veins. The 
same treatment also prevented any further loss when started 
10 days after the first laser photocoagulation [298]. Meman-
tine (5 mg/kg) significantly reduced ganglion cell loss after 
optic nerve crush in rats and memantine (1 M) blunted the 
rise in intracellular calcium seen after administration of glu-
tamate (125 M) to retinal ganglion cells in vitro [182]. Op-
tic nerve crush in Long-Evans rats led to a rise in extracellu-
lar glutamate; this rise was blocked by treatment with me-
mantine 2 mg/kg daily starting 7 days prior to injury and 
continuing for 7 days thereafter [281]. 
  In a model of glaucomatous optic neuropathy in an ex-
perimental glaucoma model in the rat, systemically applied 
memantine was injected intraperitoneally just before trabecu-
lar photocoagulation and provided neuroprotection [91]. 
  DBA/2J mice spontaneously developed essential iris at-
rophy, pigment dispersion and glaucomatous changes (in-
cluding cupping) over time. These changes were prevented 
by twice daily treatment with memantine 5 mg/kg i.p. for 4, 
6 or 9 months, with significant differences to control for the 
later two time points [245]. 
  Memantine 1 mg/kg i.m. once daily for 8 weeks pro-
tected against experimental optic nerve ischemia induced by 
chronic endothelin-1 (0.1 g/day for 8 weeks via minipumps 
to perineural region of the anterior optic nerve) in rabbits 
[121]. In another study, memantine (5 mg/kg, i.p.) given at 
the onset of ischemia protected the rabbit retina from 
changes in GABA and ChAT immunoreactivities and in-
duced a recovery of the reduced -wave of the ERG [192]. 
Oral memantine (20 mg/kg) was also neuroprotective in a 
model of acute retinal ischemia in rabbits. The effect was 
evident at later follow-up time points as assessed by func-
tional measures, but not by retinal imaging evaluating ana-
tomical hallmarks [38]. 
  A very high concentration of memantine (20 M but not 
500 M) also blocked the increased levels of CaMKII 
subunits induced by intravitreal injection of glutamate in the 
adult rat retina [140]. 
  In summary, the neuroprotective effects of memantine 
seen in various animal models of glaucoma seem to be very 
reproducible and provide a sound basis for the belief that 
memantine could be clinically neuroprotective in various 
excitotoxic diseases. As such, the results from ongoing clini-
cal trials in glaucoma are eagerly awaited as a kind of clini-
cal proof of concept. 
Huntington´s Disease 
  Following infusion of 3-NP (12 and 24 mg/kg per day 
over 28 days via osmotic minipumps) into the basal ganglia 
of 24- to 28-month-old female rats, NMDA receptor antago-
nists, including memantine (24 mg/kg/day also via osmotic 
minipumps), were ineffective [108], or even increased neu-
rodegeneration. An explanation for this contra-intuitive ob-
servation offered by the authors was the hypothesis that pro-
gressive neurodegeneration induced by low levels of energy 
may involve NMDA receptor-dependent protection of cells 
from caspase-mediated apoptosis and enhancement of 
mRNA levels of neurotrophins in the injured brain. They 
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induction of caspase activity by NMDA antagonists may be 
deleterious for neuronal survival following injuries. How-
ever, in internal studies comparing the same age, strain and 
gender of rats used in this study with young male rats usually 
used for pharmacodynamic studies, plasma levels of meman-
tine were 4.4 ± 1.6 M versus 1.3 ± 0.24 M with the same 
dosing regime (see below). As such, interpretation of the 
potential therapeutic consequences implied by the conclu-
sions of this study is problematic. However, in a recent 
study, it has been shown that memantine (0.05–2.0 GM) did 
not induce any cytotoxic effect but attenuated the stauro-
sporine-induced caspase-3 activity and LDH release in hip-
pocampal cultured neurons in vitro [111]. The mematine-
induced neuroprotection was more efficient in the hippo-
campal neurons than in the neocortical and striatal ones, 
which points to tissue specificity of effects of this neuropro-
tectant. 
  A small clinical study in Huntington’s patients already 
gave some indication for the neuroprotective activity of me-
mantine in the clinical setting [16] giving a very good reason 
to follow this indication from a preclinical perspective. 
Multiple Sclerosis 
Semi-prophylactic administration of a very high dose of 
memantine (60 mg/kg p.o. from day 7 post-inoculation (PI)) 
significantly restored BBB integrity, reduced symptoms, and 
limited inflammatory lesions in a rodent of multiple sclerosis 
- experimental allergic encephalomyelitis (EAE) in Lewis 
rats - when assessed 12 days PI [204]. In this study, thera-
peutic application of memantine was found to be as effective 
as semi-prophylactic dosing [204]. It should be stressed that 
the doses used in this study were very high. 
HIV Dementia 
  In an animal model of human immunodeficiency virus 
type 1-associated (HIV-1-associated) dementia - severe com-
bined immuno-deficient (SCID) mouse model of HIV-1 en-
cephalitis (HIVE) – memantine (5 mg/kg, i.p. daily for 7 
days) reversed the deficits observed in synaptic transmission 
and long-term potentiation (LTP) in the CA1 region of hip-
pocampal brain slices ex vivo [8]. In vitro neurotoxicity of 
the HIV-1 proteins Tat and gp120 was completely blocked 
by memantine (2 M) [183], presumably by lowering gp120-
induced increase Ca
2+ concentrations in neurons [103]. 
Lupus 
  The autoimmune antibody R4A present in Lupus patients 
binds to the channel mouth domain of NR2A and NR2B and 
increases NMDA receptor EPSCs in a voltage-independent 
manner [106]. In this study, the antibody occluded LTP 
without affecting PPF or AMPA receptors and was toxic and 
caused memory deficits. These effects provide strong sup-
port for the signal-to-noise hypothesis for NMDA receptor 
dysfunction in synaptic plasticity. Indeed, memantine 5 
mg/kg i.p. 30 minutes prior to LPS prevented hippocampal 
damage in a murine model of lupus (MAP-peptide immuni-
zation followed by LPS administration) [132]. 
Chemotherapy 
  New data indicate the potential of memantine for the pre-
vention of cognitive impairment produced by cancer therapy 
treatment. The effect of vincristine - (known to damage neu-
rons), cytarabine –(known to produce damage in the cerebel-
lum) and L-asparaginase– (known to be toxic through pro-
duction of ammonia) were studied in rats in tests for explora-
tion/cognition such as the hole board and water radial maze. 
In all models, clear impairment was noted which was pre-
vented by chronic (14 days) treatment with memantine (10 
mg/kg/day) when the test was done 24h after the last me-
mantine dose [276]. 
Symptomatological Activity 
Pain 
Inflammatory Pain
  Memantine (1 mg/kg i.p.) was very effective (75% reduc-
tion) in blocking the second phase of pain related behaviour 
following i.pl. injection of formalin in mice whilst having no 
effect on motor coordination in the rotarod test [20]. In con-
trast, although memantine suppressed biting / licking behav-
iours in the formalin test in rats at 10 and 30 mg/kg there was 
no effect at 3 mg/kg or on flinching behaviours [241]. These 
same doses also reduced the degree of paw swelling in re-
sponse to i.pl. formalin [241]. In relation to this finding, al-
though only tested at therapeutically irrelevant doses, me-
mantine inhibited the proliferation of synoviocytes in vitro
with an IC50 of 65M [195]. In studies from a different 
group using the same model in mice [279], memantine only 
preferentially inhibited the late phase at a very high dose of 
20 mg/kg i.p. – this clearly contrasts with a relatively large 
literature and the additional studies cited above. However, in 
[279] memantine produced a partial reversal of both thermal 
and mechanical hyperalgesia in rats (minimum effective dose 
(MED) of 10 and 15 mg/kg i.p., respectively) following in-
traplantar injection of carrageenan [279]. 
  In rats, very high therapeutic doses of memantine (21.5 to 
46.4 mg/kg i.p.; ED50 35.2 ± 4.7 mg/kg at the peak effect) 
dose-dependently increased the mechanical nociceptive 
threshold in a model of inflammatory pain (i.pl. carrageenan) 
and inhibited single motor unit wind-up evoked by noxious 
electrical stimulation [46]. Injection of memantine (0.1 mg, 
0.2 mg, and 1 mg) into the knee joint immediately before 
carrageenan injection (2%, 40 L), but not when adminis-
tered i.p., significantly prevented pain-related behaviours in 
rats [308]. The intra-articular injection of memantine (0.2 
mg) also suppressed c-Fos expression in the laminae I-II and 
laminae V-VI at the L3-4 spinal level and the degree of the 
spinal c-Fos expression was correlated with the extent of the 
pain-related behaviour [308]. 
Neuropathic Pain
  In a model of diabetic neuropathy, memantine (15 mg/kg 
i.p.) produced a symptomatic antinociceptive effect, whereas 
the “gold standard” gabapentin (100 mg/kg p.o.) had no sig-
nificant effect [279]. 
  Memantine showed dose-dependent (1.8-17.8 mg/kg) 
symptomatic, anti-allodynic activity in the Bennett model of 
chronic constriction injury (CCI) [161, 170] but there was 
little separation between anti-allodynic and rotarod effects. 
Co-administration with morphine or clonidine, each at 6 
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supra-additive i.e. synergistic effects (isobolographic analy-
sis) [161]. In contrast, in this same sciatic nerve injury 
model, memantine had no symptomatic effects against either 
cold and mechanical allodynia – it should be noted that 
gabapentin was also inactive against mechanical allodynia in 
this study, but was active against cold allodynia [279]. 
  Spontaneous ongoing single unit activity of spinal cord 
neurones in anesthetized rats two weeks following L5/6 spi-
nal nerve ligation showed high sensitivity to gabapentin 
(s.c.) and morphine (i.t.) administration, being significantly 
reduced in a dose-depen-dent manner [266]. In contrast, 
morphine administered via the systemic route (1, 3 and 6 
mg/kg i.v.) produced only modest and non-significant reduc-
tions of spontaneous activity. Similarly, memantine (1, 5 and 
20 mg/kg i.v.) produced only minor effects at doses known 
to be effective on wind-up in a very similar model from the 
same group [267]. 
  Intrathecal injection of memantine (300 nmol) signifi-
cantly inhibited CCI-induced mechanical allodynia [181] 
although this route of administration is very unlikely to have 
any therapeutic relevance for memantine. 
Visceral Pain
  [190] explored the role of NMDA receptors in processing 
acute visceral noxious input, compared with somatic noxious 
input. Cardiovascular responses to graded uretal distensions 
or graded pinch stimuli to one hind-paw were inhibited by 
memantine (4-32 mg/kg, i.v.) with an ID50 of 14.5 ± 1.3 
mg/kg, but these results were concluded to be due to a non-
specific action. Similarly, a high intravenous dose of me-
mantine (16 mg/kg) inhibited nociceptive responses of neu-
rones in the L6-S2 spinal dorsal horn evoked by urinary 
bladder distension to 27% of control [41]. This effect was 
selective for neurones subject to inhibition from non-
segmental cutaneous inputs (type I neurons). 
  Behavioural pain responses to visceral noxious mechani-
calstimulation were inhibited in a reversible, dose-dependent 
manner by intravenous administration of memantine (1-10 
mg/kg, i.v.) [168]. Single fibre recordings of decentralized 
pelvic nerves showed that colorectal distension responsive 
afferent nerve activity was also inhibited by memantine 
[168]. Memantine i.v. dose-dependently attenuated the action 
potential firing of vagal afferent fibres innervating the rat 
stomach response to antral distension in anesthetized rats 
with an ID50 of around 2.5 mg/kg indicating possible periph-
eral antinociceptive therapeutic utility in visceral pain [248]. 
In contrast, memantine (10–30 M) did not affect spontane-
ous or stretch-evoked firing rate of guinea pig oesophageal 
or rectal mechanoreceptors recorded extracellularly in vitro,
whereas some inhibitory effect was seen with very high con-
centrations (100-300 M) [302, 303]. 
Opioid Tolerance
  Morphine analgesia in the formalin test was increased by 
memantine (5mg/kg i.p.) [249]. Pretreatment with meman-
tine (2.5-15 mg/kg) also significantly and dose-dependently 
potentiated morphine-induced, but not fentanyl-induced 
[213], acute antinociception in the tail flick test [134, 212, 
213]. Following an acute morphine challenge, memantine 
also enhanced morphine antinociception when tests were 
conducted 120 but not 30 minutes post-mor-phine [18]. In 
contrast, others reported that memantine (3 and 10 mg/kg 
i.p.) had no effect on acute morphine or fentanyl analgesia in 
the same model [223] – drugs effects averaged over 0.5 to 
4.5 hrs. 
  All of these findings might indicate that the apparent 
synergistic antinociceptive effects could depend on the dura-
tion of the pain and the pharmacokinetics of the opioid – 
morphine has a much longer in vivo half life than fentanyl – 
and the associated development of rapid tolerance [136]. 
Indeed, confirmation for the prevention of morphine toler-
ance was seen following repeated administration of low-dose 
morphine (5 mg/kg, 8 days, once a day) - tolerance to mor-
phine analgesia was prevented by memantine (10 and 30 
mg/kg) but not dizocilpine (1 mg/kg) [61]. Memantine (3 or 
10 mg/kg) treatment also prevented morphine tolerance in 
the tail-flick test in pro-oestrous female rats and in ovariec-
tomized rats receiving 17-beta-estradiol [252]. Similarly, 
memantine treatment inhibited both the acute antinociceptive 
effect of morphine and reversed morphine tolerance in mor-
phine-tolerant mice [214].  
  Memantine (7.5 mg/kg but not 2.5 mg/kg) as well as the 
metabotropic glutamate receptor type 5 antagonist MPEP (30 
mg/kg but not 10 mg/kg) attenuated the development of tol-
erance to morphine-induced acute thermal antinociception in 
mice. When given together, the low doses of MPEP (10 
mg/kg) and memantine (2.5 mg/kg) also significantly attenu-
ated opiate tolerance. None of the treatments with glutamate 
antagonists produced antinociceptive effects or significantly 
affected acute morphine-induced antinociception in the tail 
flick test [135]. 
  The antinociceptive effects of the peripherally restricted 
opioid agonist loperamide (3-10 mg/kg) in the formalin test 
were enhanced by memantine (3 mg/kg) but not by NMDA 
receptor antagonists that don´t penetrate the blood brain bar-
rier suggesting that central NMDA receptor blockade may be 
necessary to enhance analgesia induced through peripheral 
opioid mechanisms [250]. 
Drug Dependence 
Opioids
  In accordance with previous literature, memantine (10 
mg/kg or 46.3 mol/kg, i.c.v.) inhibited naloxone-induced 
jumping in morphine-dependent mice [286]. Memantine 
attenuated (5 mg/kg) and even completely blocked (10 
mg/kg) the expression of withdrawal-potentiated startle dur-
ing naloxone (2.5 mg/kg)-precipitated withdrawal from a 
single dose of morphine sulphate (10 mg/kg). Memantine 
(2.5 or 5 mg/kg) also blocked expression of withdrawal-
induced hyperalgesia [98] and the occurrence of withdrawal-
induced aggressive behaviour at doses of 1-30 mg/kg [264]. 
  Memantine (5 and 10 mg/kg) inhibited both the acquisi-
tion and expression of conditioned place aversion (CPA) 
during withdrawal in morphine-dependent rats and also re-
duced the intensity of the physical signs of withdrawal. 
When morphine was co-administered with memantine, the 
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the physical signs of morphine withdrawal [159]. However, 
in another study where morphine (20 mg/kg) pre-treatment 
significantly potentiated the ability of naloxone (0.01-0.3 
mg/kg) to produce place aversion in mice [31], this effect 
was attenuated by D-CPPene (1 and 3 mg/kg) but not by 
memantine (1-10 mg/kg). 
  Memantine (2.5-40 mg/kg) produced neither place pref-
erence nor place aversion, but the higher doses of memantine 
tested (20 and 40 mg/kg) were able to completely block 
morphine-induced conditioned place preference [225]. Me-
mantine (7.5 mg/kg i.p.) treatment during extinction condi-
tioning abolished the ability of drug-related cues (priming 
dose of morphine) to evoke reinstatement, suggesting that 
this NMDA receptor antagonist can be useful in preventing 
relapse in opioid dependent individuals [216]. Similar effects 
were seen with higher doses (20 and 40 mg/kg) in a murine 
model of reinstatement behaviour [226]. 
  In addition, memantine (0.3-10 mg/kg) suppressed the 
self-administration of morphine (0.125-4.0 mg/kg) in rats, 
whereas MK-801 (0.1 mg/kg) was ineffective [247]. 
  However, memantine (7.5 mg/kg) inhibited the expres-
sion of place preferences conditioned with both morphine 
and sexual encounter, but had no effects in food-conditioned 
mice [215, 217]. Additionally, memantine (1, 3 or 10 mg/kg) 
dose-dependently reduced the expression of acute defensive 
behaviours (assessed using the social interaction paradigm) 
while increasing motor activity during caffeine withdrawal in 
mice [265]. These findings suggest that the effects of NMDA 
receptor blockade may not be limited to abused drug-
reinforced behaviours [217]. Since memantine administra-
tion produced an antiaggressive effect only at doses that af-
fected locomotion (20 and 40mg/kg), it is unlikely that the 
glutamatergic system mediates the antiaggressive actions of 
morphine [228]. 
  There are also positive clinical data which are beyond the 
scope of this review to discuss in detail [25, 137]. 
Cocaine
  Memantine (10 and 40 mg/kg) reverted cocaine-induced 
social withdrawal and the increase in avoidance and flight / 
escape in paired male mice [153]. Acquisition and expres-
sion of cocaine-induced place preference was prevented by 
memantine (7.5 mg/kg, i.p.) but not by the partial glycineB
site agonist ACPC (50 mg/kg, i.p.) [131]. 
  Memantine (1-10 mg/kg) attenuated expression of co-
caine-conditioned motor activity at doses that did not signifi-
cantly affect spontaneous motor activity [23] and reversed 
behavioural sensitization, an animal model for the intensifi-
cation of drug craving in cocaine addiction [151]. An effec-
tive combination was the administration of memantine with 
the D2-preferring DA agonist pergolide (0.08 mg/kg). Rein-
statement of cocaine-seeking behaviour may be disrupted by 
either D-CPPene (0.3-3 mg/kg) or memantine (1-10 mg/kg). 
However, their effects seem to depend on the reinstating 
procedure (cocaine injection versus presentation of cocaine-
associated cues) and route of cocaine administration (sys-
temic versus intracerebral), as well as upon their own motor 
stimulant effects [23]. 
  Memantine (2.5-20 mg/kg i.p.) dose-dependently de-
creased cocaine self-administration in rats trained to self-
administer cocaine (0.25 mg/infusion). Under a progressive 
ratio (PR) schedule, MK-801 (0.15 mg/kg i.p.) increased the 
number of cocaine infusions in a manner similar to increas-
ing the unit dose of cocaine, suggestive of potentiation of 
cocaine reward. Conversely, memantine (10 mg/kg i.p.) pro-
duced rate-decreasing effects on the PR schedule [107]. 
Similarly, pre-treatment with memantine protected against 
cocaine-induced convulsions with an ID50 of 16mg/kg [33]. 
  Memantine (0.3-3 mg/kg via i.v. infusion) was tested in 
Rhesus monkeys trained to press levers reinforced with ei-
ther cocaine-associated stimuli or 30 g/kg cocaine infusion. 
The results were taken to suggest that memantine may in-
deed attenuate the conditioned reinforcing effects of cocaine-
associated stimuli, but may also increase levels of cocaine 
self-administration [185]. 
  Amphetamine-induced increases in carrier-mediated do-
pamine release in slices of rat nucleus accumbens (NAcc) 
and this effect was reversed to control levels by memantine 
(1M), but not by (+)MK-801 (0.1 and 1 M). The authors 
ascribe this difference to a possible involvement of NR1a/ 
NR2D subunits in this tissue and suggest possible therapeu-
tic relevance for treating drug dependence [56]. 
  There are also clinical data indicating a lack of abuse 
liability in cocaine addicts which are beyond the scope of 
this review to discuss in detail [50, 282]. 
Ethanol
  Acute administration of memantine (10 mg/kg i.p.) in-
duced an upregulation of NR1-1/NR1-2 and NR2B protein 
levels in the hippocampus and cortex, respectively [219]. 
Interestingly, this modulation of subunit expression was 
similar to the anti-craving compound acamprosate. Addition-
ally, ethanol (50 mM) - induced upregulation of NMDA re-
ceptor protein (NR1, NR2A and NR2B) in cultured rat hip-
pocampal neurons, was completely prevented by memantine 
(10 M for 5 days; [160]). 
  Withdrawal from chronic (6 month) alcohol ingestion 
produced robust learning deficits in rats in the Morris water 
maze. Treatment with memantine starting at the beginning of 
the withdrawal phase (20 mg/kg bolus followed by 1 mg/kg 
every 12 h for 4 weeks) resulted in a complete reversal of 
these behavioural impairments [158]. In a similar model, 
memantine also dose-dependently (1-10 mg/kg, i.p.) sup-
pressed ethanol withdrawal seizures [24, 130]. Repeated 
memantine administration decreased the acute motor impair-
ing effects of ethanol [186]. 
  Koros and collegues [125] assessed the effects of re-
straint stress and memantine (2.25 or 4.5 mg/kg) on the dose-
response curve of ethanol discrimination. Stress did not alter 
the rate of responding. However, both doses of memantine 
tended to increase the rate of responding when given in 
combination with lower doses of ethanol (0.25-0.5 g/kg). In 
contrast, 4.5 mg/kg memantine decreased the response rate 
when combined with 1 g/kg ethanol. These results suggest 
that: (1) pre-exposure to acute restraint stress or memantine 
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nation; (2) memantine given in combination with low doses 
of ethanol may enhance the discriminative stimulus of etha-
nol but inhibits at high ethanol doses. Accordingly, the me-
mantine-induced decrease in experimental ethanol craving 
[104] may not be related to alterations in the cueing proper-
ties of ethanol.  
  Memantine (13 mg/kg per day) also prevented the in-
crease in the consumption of saccharin after a 1-week depri-
vation from free-choice, unlimited access to saccharin (0.1%, 
w/v) [306] indicating that the previously observed inhibitory 
action in a similar model following alcohol deprivation can 
be extended to other conditions of excessive drug/alcohol/ 
food intake. However, studies on the behavioural specificity 
of memantine on alcohol drinking in a schedule-induced 
polydipsia (SIP) task in C57BL/6J mice indicate that drug 
induced reduction in alcohol drinking was associated with 
other behavioural effects that included reduction in regula-
tory drinking, bringing into doubt the therapeutic possibility 
for ameliorating human alcohol addiction [68]. Finally, when 
administered concurrently with binge ethanol exposure, can-
nabidiol and antioxidants protected against hippocampal and 
entorhinal cortical neurodegeneration in a dose-dependent 
fashion whereas memantine (30 mg/kg/ day as 6*5 mg/kg) 
was without effect [94]. 
  Nonetheless, there are some positive clinical data which 
are beyond the scope of this review to discuss in detail [26, 
138]. 
Epilepsy
  Memantine effectively prevented both clonic and tonic 
components of pentylenetetrazole-induced (35 mg/kg i.p.) 
kindling starting at a dose of 3 mg/kg i.p. [156]. Similar ef-
fects were seen against NMDA convulsions whereas ataxic 
side effects were first seen at doses some 6-fold higher [157, 
235]. 
Anxiety
  In our review from 1999 the available data did not give 
support for anxiolytic activity of memantine in animal mod-
els that could possibly be translated into efficacy in humans. 
Newer data have since been published that support this no-
tion. Memantine (1.25 - 5 mg/kg i.p.) was also inactive in a 
different rat model of anxiety to those previously reported 
for memantine - the conditioned emotional response [175]. 
Moreover, in an illuminated platform avoidance task in rats, 
memantine (20 g), injected into the ventromedial hypo-
thalamus, actually increased anxiety [270]. Similarly, me-
mantine 5 mg/kg/i.p. daily for 7 days had no effect on stress-
induced increases in hippocampal nitrogen oxides in an ani-
mal model of post-traumatic stress disorder (sequential expo-
sure of the animals to restraint stress, forced swim stress and 
finally halothane vapours, followed 7 days later with a brief 
re-stress forced swimming) [99]. 
  However, memantine (4.0 and 8.0 mg/kg) did show anx-
iolytic effects in rats in the elevated plus-maze (EPM) in a 
study by [21] and these effects, as for other anxiolytic com-
pounds tested, diminished after repeated testing exposure but 
not after repeated drug administration i.e. after adoption of 
an anxiolytic-insensitive behavioural strategy by the animals 
– the so called 'one-trial tolerance' phenomenon. Scopola-
mine (0.5-1.5 mg/kg) impaired the acquisition of this behav-
ioural strategy to cope with the subsequent EPM exposure 
and thereby revealed the anxiolytic-like effects of memantine 
in a repeat trial [22].  
Depression 
  Memantine produced a dose-dependent (2.5-15 mg/kg) 
antidepressant-like effect in the tail-suspension test; and the 
antidepressant-like effect of the highest memantine dose of 
15 mg/kg appeared to persist with sub-chronic administration 
of memantine (3 days, twice daily) [126]. In the same study, 
when administered acutely 5 min before testing in the open 
field, memantine reduced rearing (1.875-30 mg/kg), ambula-
tion (7.5 and 30 mg/kg) and grooming (30 mg/kg). As meas-
ured in three different tests, ataxia and stereotypy appeared 
only at the single highest dose of 30 mg/kg, 5 and 35 min 
after administration. In mice treated for 3 days, twice daily, 
the dose of 30 mg/kg continued to increase ambulation and 
decrease rearing and grooming, but no signs of ataxia and 
stereotypy were detected. These data indicate that different 
doses of memantine are required for therapeutic and side-
effects, and that tolerance may develop to some of the side 
effects e.g. ataxia, but not to therapeutic effects e.g. antide-
pressant-like actions [126]. 
  Memantine (1-3mg/kg) also produced antidepressant-like 
effects in the forced swimming test (FST) in mice that 
seemed to be mediated through an interaction with the l-
arginine-NO-cGMP pathway [5] and dependent on the cellu-
lar signalling modulated by PKA, CaMKII and MAPK/ERK, 
but not by PKC [6]. 
  Memantine (2.5 and 5 mg/kg) showed synergistic antide-
pressant activity when combined with imipramine, ven-
lafaxine and fluoxetine in the FST in rats [232]. Moreover, 
memantine (10 mg/kg) prevented the development of hyper-
thermia and the increase in noradrenaline levels in the ante-
rior hypothalamus following administration of serotonin 
(100 mg/kg) and clorgyline (2 mg/kg) – an animal model of 
serotonin syndrome, one of the most serious side effect of 
some classical antidepressants [188]. Combination of sigma 
ligands with memantine at low doses that were without effect 
on their own (SA4503 1-10 mg/kg; siramesine 1-3 mg/kg; 
1,3 di-0-tolylguanidine (DTG) 2.5 and 5 mg/kg; memantine 
2.5 mg/kg i.p.) also decreased immobility time in the FST in 
rats [255, 256]. This effect was antagonized by sigma recep-
tor antagonists.  
  However, memantine (10 mg/kg i.p.) had no effect on the 
CNS expression pattern of the vesicular glutamate trans-
porter VGLUT1, upregulation of which has been proposed to 
be a useful marker for antidepressant activity [178]. Most 
importantly, in a small, double-blind, placebo-controlled 
clinical study, in 30 subjects with major depression, meman-
tine (5-20 mg/day) (n = 14) for 8 weeks failed to show a sig-
nificant antidepressant effect compared to placebo (n= 16) 
[307]. 
Parkinson´s Disease 
  As previously well documented, memantine was con-
firmed to block haloperidol-induced catalepsy starting at a 
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mice, memantine (5 mg/kg i.p.) had no significant effect on 
dopamine or 3,4-dihydroxyphenyl-acetic acid (DOPAC) 
levels [84]. However, homovanillic acid in MPTP-treated 
mice was claimed to be increased by 300% and this effect 
was attributed to possible sparing of dopaminergic neurons – 
but there were some discrepancies in the tabular data (e.g. 
the methods state 5 mg/kg but the legends state 0.5 mg/kg) 
[84]. 
  Intranigral administration of glutamate to rats with Park-
insonian syndrome induced by MPTP augmented the devel-
opment of Parkinsonian symptoms (oligokinesia and muscu-
lar rigidity), but did not affect motor activity of intact ani-
mals [139]. Memantine administered i.p. in parallel with the 
induction of Parkinsonian syndrome weakened the develop-
ment of oligokinesia and muscular rigidity in a dose-depen-
dent manner starting from 5 mg/kg and abolished the toxic 
effect of glutamate [139].  
  In the substantia nigra and corpus striatum of reserpine-
treatedrats,acuteinjection of memantine (40 mg/kg) strongly 
increased L-DOPA decarboxylase (DDC), whilst not affect-
ing or decreasing 5- HTPDC activity [72]. L-DOPA (25 
mg/kg) on its own inhibited both enzymes in either brain 
region. The ability to increase the activity of DDC could be 
clinically important in the treatment of Parkinson’s disease, 
where the disappearance of DDC caused by the degeneration 
of nigrostriatal dopamine could contribute to the eventual 
loss of effectiveness of dopamine replacement therapy with 
L-DOPA. 
  One group suggested a putative benefit of memantine as 
an anti-Parkinsonian agent on the basis of its synergistic in-
teractions with L-Dopa i.e. following co-administration of 
memantine (0.3 to 3 mg/kg) with sub threshold (5 mg/kg) or 
suprathreshold doses (20 mg/kg) of L-Dopa to hypokinesic 
drug-naïve or L-DOPA-tolerant MPTP-treated mice [12, 78, 
79]; see also [13]).  
Tardive Dyskinesia 
  Memantine inhibited the development of haloperidol-
induced persistent vacuous chewing movements (VCD) and 
attenuated the increase in preproenkephalin mRNA expres-
sion in a rat model of tardive dyskinesia, in which VCM 
were induced by 20 weeks of haloperidol administration 
[10]. 
Cancer 
  Even though the effective doses of memantine in this 
section are far beyond therapeutically relevant concentra-
tions, we here summarize the potential effects of memantine 
against cancer for the sake of completeness. 
  When host rats were treated with very high doses of me-
mantine (25 mg/kg twice daily, i.p.), an implanted glioma 
cell line secreting glutamate (RG2Glu+) responded with a 
small, but significant, decrease in tumour volume [269]. 
Memantine also restricted the growth of C6Glu+ tumours 
(subcloned C6 cells which also actively release glutamate). 
  On the other hand, in vitro memantine did not reduce 
proliferation of cultured C6Glu+cells or RG2 glioma cells at 
therapeutically achievable concentrations although a signifi-
cant reduction in proliferation of both cell types occurred at 
huge concentrations of 100-400 MM [269]. Memantine also 
inhibited in vitro growth of ten human cancer cell lines (four 
prostate, two breast and four colon) with half-maximal 
growth inhibition at very high concentrations of memantine 
(23 to 92 M) [1]. Finally, a very high concentration of me-
mantine (50M) caused a rapid and reversible change in 
melanocyte morphology, which was associated with disor-
ganisation of actin and tubulin microfilaments that could 
have implications in the treatment of melanoma [105]. In all 
cases, the concentrations of memantine required in vitro are 
probably far too high to be of any real therapeutic relevance. 
  The open question is therefore the disaccord between the 
in vivo and in vitro data. This could be explained by the the-
ory that aggressive CNS tumours make “place” for their own 
expansion in the brain by releasing glutamate and destroying 
neurones via excitotoxic mechanisms. 
Diabetes 
  Memantine (4 mg/kg/day for 8 weeks) prevented loss of 
gastric NO neurons and reduction of nNOS protein expres-
sion in an animal model of diabetes when administered 3 
days after induction of diabetes with streptozotocin (STZ) 
[193]. Diabetes results in various biochemical abnormalities 
such as elevation of glutamate in the retina. Post mortem 
incubation of the retina of diabetic rats with memantine (30 
M) inhibited such elevations [133].  
Other 
  The incidence of myocardial ischemia-induced ventricu-
lar tachycardia, ventricular fibrillation and mortality was not 
modified by treatment of rats with memantine (1.5 mg/kg), 
injected 5 minutes prior to occlusion. However, the inci-
dence of ventricular tachy-cardia, ventricular fibrillation and 
mortality induced by myocardial ischemia-reperfusion was 
significantly reduced by memantine, and MK-801 and keta-
mine [53]. 
  NMDA receptor channel blockade has also been tested 
on aggression in isolated male mice by the resident-intruder 
procedure [17]. Memantine (1-30 mg/kg) inhibited expres-
sion of aggressive behaviours only at doses that produced 
ataxia and thus, does not exert selective effects on aggres-
sion. 
SIDE EFFECTS 
  Memantine disrupted prepulse inhibition (PPI) in an 
acoustic startle gating test at high, supra-therapeutic doses 
(10 and 17 mg/kg i.p.) but not at lower doses of 1 and 3 mg/ 
kg. Furthermore, the magnitude of this disruption was re-
duced relative to high-affinity ligands like (+)MK-801 [295]. 
Another group showed that memantine (10 mg/kg) actually 
increased PPI at short prepulse-pulse intervals (10-20 ms), 
while inhibition was confirmed at longer intervals (60-120 
ms). A higher dose (20 mg/kg) had only inhibitory effects. 
Ketamine produced similar effects but enhancement of PPI 
was less evident. The effect of memantine was attenuated by 
an atypical neuroleptic, quetiapine, but not by haloperidol, 
which seems to be characteristic for NMDA receptor an-
tagonists. This group is planning a study of memantine in 
humans, where ketamine has an enhancing effect upon pre-70 Current Neuropharmacology, 2008, Vol. 6, No. 1 Rammes et al. 
pulse inhibition and a similar effect is expected from me-
mantine [268]. 
  Potential modifications of the behavioural profile of me-
mantine following long-term administration was assessed by 
[101]. When memantine (20 mg/kg/day) was either infused 
or repeatedly injected for 14 days, tolerance was observed to 
the learning impairing and ataxic effects seen at acute high 
doses after both repeated administration and infusion. Sensi-
tization to the locomotor stimulation was seen only follow-
ing repetitive injections but not infusion of memantine, 
which is the therapeutically more relevant route of admini-
stration. 
  In organotypic hippocampal cultures chronic treatment 
with memantine at 1M for 17-23 days had no effect on 
bicuculline seizures and actually increased cell death in the 
DG. Similar results were obtained with the competitive and 
glycine site antagonists APV (50M) and DCKA (100M). 
In contrast, the NR2B selective antagonist Ro-25 6981 
(1M) was protective following chronic, but not acute, ad-
ministration. It should be noted that the chosen concentration 
for memantine was close to its therapeutic range whereas 
that of the NR2B antagonist was far above the IC50 for 
NR2B receptors [284]. 
  In summary, the additional non-clinical studies con-
ducted with memantine since our review in 1999 did not 
reveal any new signalss for potential side effects, drug-drug 
interactions or toxic changes attributable either to memantine 
or to it’s known degradation products for therapeutic doses 
relevant for the treatment of AD.  
Abuse Potential 
  Memantine has been used in clinical practice for over 20 
years, during which no cases of abuse have been reported. 
However, given the fact that memantine has partially over-
lapping pharmacology with some drugs that are indeed 
abused (mainly in the USA) such as ketamine or PCP, it is 
important to analyze data from animal models related to 
abuse potential of these agents.  
  It should be stressed that, based on plasma levels, an 
acute dose of 5 mg/kg acute or s.c. infusion of 20 mg/kg/day 
is the maximum dose that can be considered therapeutically 
relevant in rats since such treatment leads to a ca. 1 M
plasma concentration which is the maximal concentration 
seen in humans treated therapeutically with memantine [55]. 
  In a drug discrimination paradigm in rats based on lever 
pressing (indicative of subjective drug effects), memantine 
partially substituted for PCP first at a dose of 10 mg/kg but a 
50 % decrease of the response rate was also seen at this dose 
which probably reflects myorelaxant activity [240]. In mon-
keys a similar picture was seen, i.e. memantine produced 
PCP-like responding only at doses of 5 mg/kg and above, i.e. 
at doses that produced a decrease in response rate and which 
are very high doses in this species [187]. In contrast, the high 
affinity antagonist (+)MK-801 caused substitution for PCP at 
doses which did not impair performance. 
  Also, in contrast to PCP, memantine did not substitute for 
cocaine [240]. However, when site-specific NMDA receptor 
antagonists were examined against intravenous cocaine self-
administration (0.24 mg/infusion), memantine (2.5-20 mg/ 
kg,i.p.) and MK-801 (0.05-0.2 mg/kg, i.p.) dose-dependently 
decreased the number of cocaine infusions [107]. Antago-
nists at other NMDA receptor sites, L-701,324 (glycineB,
1.25-10 mg/kg p.o.) and CGP 39551 (competitive, 2.5-15 
mg/kg, i.p.) were without effect. Memantine (0.3-3 mg/kg 
via i.v. infusion) was also tested in Rhesus monkeys trained 
to press levers reinforced with either cocaine-associated 
stimuli or 30 g/kg cocaine infusion. The results were taken 
to suggest that memantine may indeed attenuate the condi-
tioned reinforcing effects of cocaine-associated stimuli, but 
may also increase levels of cocaine self-administration [185]. 
  Memantine produced only variable self administration in 
monkeys [187]. Memantine was 2-3 times less effectively 
self administered than PCP, and the effect was very variable 
depending on the monkey and the test day, and the maximum 
effect was very weak. According to the author's calculations, 
in order to obtain equivalent PCP-like intoxication in hu-
mans, a dose over 150 mg (p. o.) must be used, which is 7-15 
times higher than the usual therapeutic dose. An important 
aspect is that all of the monkeys used in this study had an 
history of PCP or cocaine use which probably made them 
more prone for demonstration of self-administration of me-
mantine. This claim is, in fact, supported by another unpub-
lished study where pentobarbital was used to train the mon-
keys. All four rhesus moneys in the study did self administer 
pentobarbital at least 16 times a day for 3 consecutive days. 
When pentobarbital was replaced with memantine, the self-
administration rate was similar to that of saline. Moreover, 
even forced administration of memantine (1mg/kg per infu-
sion) did not initiate self administration. 
  Memantine did not produce place preference on its own, 
indicating that it has no reinforcing potential in this test [131, 
211]. Consistently, dopamine levels were not affected in 
medial prefrontal cortex by an acute administration of me-
mantine (20 mg/kg, i.p.) which also indicates that memantine 
is unlikely to possess psychotomimetic activity at therapeuti-
cally relevant doses [102]. 
  In a self-stimulation test memantine, at doses up to 17 
mg/kg, did not have a significant effect on the current fre-
quency threshold for self-stimulation – only a slight increase 
was seen at 10 mg/kg. In contrast, (+)MK-801 decreased the 
threshold in a range of doses 0.1-0.4 mg/kg i.e. the current 
intensity that was previously not reinforcing, gained rein-
forcing value. This indicates substantial differences between 
different NMDA receptor channel blockers and demonstrates 
that memantine, in contrast to (+)MK-801, is most likely 
devoid of abuse potential [273, 274]. 
  Chronic treatment with memantine did not result in sensi-
tization of the behavioural response, in contrast to the other 
NMDA receptor antagonist (+)MK-801 [151]. 
  In summary, most studies cited above indicate clearly 
that, at therapeutic doses, memantine has no abuse potential, 
but in contrast might actually inhibit abuse of addictive drugs 
such as morphine or ethanol (see above). The effects on co-
caine abuse are more controversial as, in monkeys, meman-
tine inhibited the reinforcing effects of conditioned stimuli 
but may have enhanced cocaine self-adminis-tration [185]. 
On the other hand, in rats, memantine produces rate “de-Pharmacodynamics of Memantine  Current Neuropharmacology, 2008, Vol. 6, No. 1  71
creasing” effects under a progressive ratio of cocaine self-
administration. 
  Therefore, although it cannot be completely excluded that 
memantine could be abused by a population with a history of 
abuse of drugs with overlapping pharmacology such as PCP 
or ketamine, this probably has little relevance for the treat-
ment population i.e. AD patients. 
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